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Abstract 
Changes in systolic blood pressure (SBP) during an admission tor acute heart failure (AHF), especially 
those leading to hypotension, have been suggested to increase the risk of adverse outcomes.  
Methods: We analysed the association of SBP decrease during the first 24 hours from randomisation 
with serum creatinine changes at the last time point available (72 hours), using linear regression, and 
with 30- and 180-day outcomes, using Cox regression in 1257 patients in the VERITAS study. 
Results: After multivariable adjustment including baseline SBP, greater SBP decrease at 24 hours from 
randomisation was associated with greater creatinine increase at 72 hours and greater risk of 30-day all-
cause death, worsening HF or HF readmission. The HR for each 1 mmHg decrease in SBP at 24 hours for 
30-day death, worsening HF or  HF rehospitalisation was 1.01 (95% CI 1.00-1.02, p=0.021). Equally, the 
HR for each 1 mmHg decrease in SBP at 24 hours for 180-day all-cause mortality was 1.01 (95% CI 1.00-
1.03, p=0.038). The associations of SBP decrease with outcomes did not differ by tezosentan treatment 
group, although tezosentan treatment was associated with a greater SBP decrease at 24 hours.  
Conclusions: In the current post-hoc analysis, SBP decrease during the first 24 hours was associated with 
increased renal impairment and adverse outcomes at 30 and 180 days. Caution, with special attention to 
blood pressure monitoring, should be exercised when giving vasodilating agents to AHF patients.  
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Introduction 
Vasodilating agents are among the recommended first-line therapies in patients admitted for acute 
heart failure (AHF)(1,2) despite a lack of evidence supporting their efficacy beyond the first hours of 
admission (3). A drop in systolic blood pressure (SBP) during the first days of admission has been 
observed in several studies (4-6); however, the predictors of SBP decreases and the associations of such 
blood pressure decreases with outcomes were not reported in detail. An analysis of one small study did 
suggest that SBP reduction may be associated with untoward pathophysiological effects such as 
worsening of kidney function (7). Such a potential deleterious effect of a SBP decrease may explain, at 
least in part, the results of some clinical studies where pharmacologically induced SBP decreased, 
leading to renal function deterioration and subsequent adverse outcomes (8-10). This conclusion was 
strengthened by a recent analysis of the Acute Study of Clinical Effectiveness of Nesiritide in 
Decompensated Heart Failure (ASCEND-HF) trial which suggested that hypotension is  relatively 
common during AHF hospitalisation, and carries a significant negative prognostic impact on 30-day 
outcomes (11).  In the current manuscript, we assess predictors of SBP changes at 24 hours from study 
drug initiation (24-48 hours from admission) and their associations with worsening kidney function and 
clinical outcomes in the Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure 
Studies (VERITAS) (4,5).  
 
Methods 
The VERITAS study comprised two, identical, concurrent randomised trials that evaluated the efficacy of 
tezosentan administration within 24 hours of hospital presentation for AHF (4,5). Patients were included 
who reported dyspnea at rest after receipt of intravenous diuretics and who had at least two of four 
objective heart failure signs: elevated natriuretic peptides; pulmonary edema on physical examination; 
pulmonary congestion or edema on chest x-ray; or left ventricular systolic dysfunction evidenced by 
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reduced ejection fraction or wall motion index.  Patients with a SBP ≤ 100 mHg, or ≤ 120 mmHg if 
receiving a vasodilator, were excluded. Patients enrolled in error more than 24 hours after presentation 
and patients without a measured SBP at 24 hours were excluded from the analyses. 
Routine laboratory measures at baseline, 24 and 72 hours were obtained locally, while troponin I and B-
type natriuretic peptide (BNP) were assayed centrally.  Patients were followed for worsening heart 
failure through 30 days, and vital status was assessed at six months. 
 
Statistical analysis 
Summary statistics reported for continuous variables are the mean and standard deviation, or the 
median (IQR) for skewed variables; proportions in each category are presented for categorical variables.   
Patients were grouped by tertiles of the change in SBP from baseline to 24 hours and baseline 
characteristics compared using ANOVA or Cochran-Mantel-Haenszel chi-square tests, as appropriate.   
Linear regression was used to model the associations of baseline characteristics with the change in SBP 
from baseline to 24 hours.  Non-linearity of the association between each continuous variable and SBP 
change was assessed by testing the contribution of the non-linear terms of a restricted cubic spline 
transformation with four knots.  A linear spline, quadratric or cubic polynomial, or log transformation 
was chosen, based on the Akaike’s Information Criterion, to model non-linear associations.  Ten multiple 
imputation datasets assuming multivariate normality were used for missing baseline covariates (11), and 
parameter estimates were averaged over these imputation datasets using Rubin’s algorithm (14). A 
multivariable model was selected in each imputation dataset from among the baseline characteristics 
using backwards elimination with a retention criterion of P<0.05; the final model included those 
covariates included in at least 6 of the 10 imputation datasets. The unadjusted association of SBP 
change at 24 hours with creatinine change at 72 hours was assessed using linear regression. Logistic 
regression was used to provide the odds ratios for the association between SBP change at 24 hours and 
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an increase in creatinine of ≥0.3 mg/dL at 72 hours, with covariates for multivariable adjustment 
selected using the same methodology as above.   
Associations between the SBP changes and 30-day all-cause death or HF readmission and 180-day all-
cause death were examined using Cox proportional hazards models.  Potential confounding was 
addressed through multivariable adjustment for baseline SBP and covariates previously found to be 
prognostic of these outcomes (14). 
SAS® 9.3 (SAS Institute, Inc., Cary, NC, USA) was used for all analyses. 
 
Results 
Of the 1449 patients randomised, 102 who were enrolled more than 24 hours from presentation were 
excluded and 90 patients were missing the change in SBP at 24 hours, leaving 1257 patients for analysis.   
Patients’ baseline characteristics by tertiles of SBP change at 24 hours are presented in table 1. 
Unadjusted and multivariable-adjusted associations of baseline characteristics and SBP decrease at 24 
hours are presented in table 2. Predictors of a larger SBP drop at 24 hours were lack of atrial fibrillation 
or diabetes mellitus, higher baseline SBP, longer QRS interval, higher BUN, and lower WBC count.  
Respiratory rate, heart rate, and creatinine had non-linear relationships with SBP change. Tezosentan 
treatment was associated with a larger mean SBP decrease at 24 hours (mean difference 6.17, 95% CI 
4.39-7.96, p<0.001).  
SBP change at 24 hours was inversely associated with change in creatinine at 72 hours (figure 1). The 
relationship had an inflection point around -15 mmHg; i.e., SBP decreases > 15 mmHg were associated 
with a numerical acceleration in creatinine increase, although the departure from non-linearity was not 
statistically significant (p=0.5910). Overall, 222 (20.8%) patients had a creatinine change of ≥ 0.3 mg/dL 
at 72 hours. Patients with larger decreases in SBP at 24 hours were more likely to have a creatinine 
change ≥ 0.3 mg/dL at 72 hours (OR per 1-mmHg greater decrease in SBP 1.01, 95% CI 1.00-1.02, 
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p=0.0272).  The association of SBP change with creatinine increase did not differ significantly by 
tezosentan treatment (interaction p=0.7239). After multivariable adjustment for factors found to be 
associated with creatinine change ≥ 0.3 mg/dL at 72 hours in the VERITAS database (Supplemental 
Table) - age, renal impairment, time from admission to randomization, respiratory rate, and eGFR – the 
association of SBP change with a creatinine change ≥ 0.3 mg/dL was of borderline statistical significance 
(OR per 1 mmHg decrease in SBP 1.01, 95% CI 1.00-1.01, p=0.0941).  Tezosentan treatment was not 
significantly associated with the risk of a creatinine increase ≥ 0.3 mg/dL, and further adjustment for 
tezosentan treatment did not affect the association of SBP change with the outcome. 
Similarly, SBP decrease at 24 hours was associated with a greater risk of adverse outcomes at both 30 
and 180 days. All-cause death, worsening HF or HF readmission through 30 days occurred in 395/1257 
(31.4%) patients and 165/1257 (13.1%) died through day 180.  After multivariable adjustment, the HR 
for each 1-mmHg decrease in SBP at 24 hours for 30-day death, worsening HF or  HF rehospitalisation 
was 1.01 (95% CI 1.00-1.02, p=0.021), and this association did not differ by randomised treatment 
(interaction p=0.3409). A larger decrease at 24 hours in SBP was also associated with increased risk of 
all-cause mortality at 180 days. For 30-day death, WHF or HF readmission, covariates for multivariable 
adjustment were age, heart rate, respiratory rate, history of CHF, history of diabetes, history of COPD, 
systolic blood pressure, renal impairment, baseline dyspnea VAS, albumin, BUN, hemoglobin, and 
sodium (13).  For 180-day all-cause death these were age, heart rate, history of IHD/PVD/Stroke, systolic 
blood pressure, baseline dyspnea VAS,  history of COPD, albumin, BUN, WBC and sodium (13).  After 
multivariable adjustment, the HR for each 1 mmHg decrease in SBP at 24 hours for 180-day all-cause 
mortality was 1.01 (95% CI 1.00-1.03 p=0.038). There was no interaction between SBP decrease and 
outcomes in tezosentan-treated versus placebo-treated patients (interaction p=0.1414). Figure 2 depicts 
the association of 180-day mortality with SBP decrease at different time points through 24 hours, 
suggesting a lack of significance in the first 12 hours and an increased effect of SBP decrease with time.  
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Discussion 
The present analysis of VERITAS suggests an inverse correlation between SBP changes and renal function 
as measured by creatinine changes at 72 hours, as well as 30- and 180-day outcomes in patients with 
AHF. Patients with larger decreases in blood pressure were especially prone to creatinine increases as 
well as increased risks of 30-day death, worsening HF or HF readmission, and 180-day mortality.  
The results of these analyses are largely in line with those of previous studies, although confirming and 
supplementing them. In a small analysis of the Pre-RELAX-AHF phase 2 study, Voors et al (7) have shown 
that BP decrease is associated with renal function deterioration. An analysis of the larger ASCEND-HF 
study (11), has demonstrated that hypotension, strictly defined as SBP decrease to < 90 mmHg 
regardless of initial BP, was associated with increased risk of adverse outcome at 30 days, but not with 
renal impairment at day 10 or discharge. As the restrictions imposed by the selection of the subgroup 
analysed in ASCEND-HF (i.e., pts with hypotension defined by a specific cut-off and assessment of renal 
function distant from the event) limit the analysis to a specific subgroup of patients, it is possible that a 
relative decrease in SBP rather than reaching an arbitrary threshold is more important prognosticaly. 
Indeed, in the present analysis baseline-adjusted SBP decreases were associated with both more 
adverse outcomes and more renal impairment, regardless of baseline SBP of magnitude of decrease in 
SBP.  
The relationship between SBP changes and outcomes after vasodilating agents has not been thoroughly 
studied in the past. In the current analysis, no interaction was found between the association of SBP 
decrease, drug therapy and outcomes (p=0.1414 for 180 days mortality), although as reported 
previously, active therapy with tezosentan was associated with a greater SBP decrease. Thus, the 
increased risk associated with larger drop in SBP may have neutralised the beneficial effects of the new 
treatment.  
8 
 
 
Other previous studies have suggested that such SBP lowering induced by active interventions may lead 
to more adverse outcomes.  In earlier studies where doses of nesiritide higher than those given in 
ASCEND-HF were administered, nesiritide therapy led to more hypotension, renal impairment and 
increased mortality (9). This finding was however not replicated in the ASCEND-HF study where lower 
doses of nesiritide were administered. In the REVIVE study, similar findings were reported with more 
hypotension in the active arm which was associated with a trend towards earlier mortality (8), especially 
in patients enrolled with lower BP at screening. Finally, in the recently reported TRUE-AHF study, 
administration of ularitide was associated with a greater SBP decrease in the active arm (approximately 
10 mmHg at 24 hours), an increase in creatinine and a numerical increase in early mortality at 180-240 
days (10). These results can be explained by some negative effects of BP decrease on end organ 
perfusion such as kidneys (7), although data on the mechanism of why such BP decrease may be 
detrimental are not available. These findings may be an underestimation of the true negative effects of 
BP reduction in AHF as creatinine is not a perfect measure of kidney dysfunction (15). On the other 
hand, no studies examining the effects of agents with vasodilating effects have ever demonstrated 
beneficial effects in patients with AHF beyond the first few hours of admission. Most importantly, the 
effects of IV nitrates administration beyond the first 1-2 hours of admission have never been examined 
in detail, and despite that these agents are recommended in the guidelines for the treatment of AHF (1). 
Interestingly, our data also show that early changes in SBP have no relationship with outcomes whereas 
the changes occurring beyond 12 hours from admission are associated with worse outcomes. Hence, the 
totality of the evidence – both the current and previous analyses as well as prospective studies – begs 
the question whether vasodilatation, long held as a pillar of therapy for AHF, does indeed benefit 
patients beyond the first hours of administration, especially once normal values of SBP are reached. 
These data would suggest that our knowledge of the effects of vasodilatation in AHF is incomplete and 
studies to examine such effects may be urgently needed. In the meantime, physicians should exercise 
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caution when administering vasodilating agents to patients with AHF, especially when they cause 
significant reduction of SBP > 15-25 mmHg or a low SBP is reached.  
 
Limitations 
The current analysis is a post-hoc analysis from the VERITAS and as such should be seen as hypothesis-
generating and not definitive.  
 
Conclusions 
Systolic blood pressure decreases in patients with AHF are associated with more early renal impairment 
and an increase in adverse outcomes at 30 and 180 days. Studies examining the effect of vasodilating 
agents such as IV nitrates in AHF are urgently needed, and until such studies are performed caution 
should be exerted in the administration of these agents to patients with AHF especially when significant 
falls in SBP are observed.  
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Table 1: Baseline Characteristics by Tertiles of Systolic BP Change to 24 Hours  
 Statistic 
SysBP Chg (<= -19) 
(N=423) 
SysBP Chg (>-19 to <=-3) 
(N=424) 
SysBP Chg (> -3) 
(N=410) P-value [1] 
Overall 
(N=1257) 
Age (years) Mean (SD) 71.0 (12.01) 69.9 (11.93) 69.9 (12.49) 0.3321 70.3 (12.14) 
Gender: Males n (%) 238 (56.3%) 263 (62.0%) 241 (58.8%) 0.4522 742 (59.0%) 
Race: White n (%) 353 (83.5%) 371 (87.5%) 362 (88.3%) 0.0409 1086 (86.4%) 
Time to randomization (hours) Mean (SD) 10.2 (6.64) 10.9 (7.02) 11.4 (6.87) 0.0423 10.8 (6.86) 
BMI (kg/m2) Mean (SD) 29.2 (6.47) 28.8 (6.01) 28.9 (6.28) 0.7039 28.9 (6.25) 
Treated with Tezosentan n (%) 242 (57.2%) 242 (57.1%) 157 (38.3%) <.0001 641 (51.0%) 
Atrial fibrillation on admission n (%) 96 (22.7%) 112 (26.7%) 118 (29.1%) 0.0364 326 (26.2%) 
History of CHF n (%) 299 (70.9%) 325 (77.4%) 291 (71.9%) 0.7249 915 (73.4%) 
History of COPD n (%) 74 (17.5%) 84 (19.9%) 74 (18.0%) 0.8303 232 (18.5%) 
History of diabetes n (%) 211 (49.9%) 216 (51.1%) 184 (44.9%) 0.1519 611 (48.6%) 
History of hyperlipidemia n (%) 142 (33.6%) 158 (37.4%) 145 (35.4%) 0.5818 445 (35.4%) 
History of hypertension n (%) 361 (85.3%) 329 (77.8%) 317 (77.3%) 0.0035 1007 (80.2%) 
History of smoking n (%) 28 (6.6%) 31 (7.3%) 37 (9.0%) 0.1926 96 (7.6%) 
History of IHD, PVD, stroke n (%) 284 (67.1%) 302 (71.4%) 294 (71.7%) 0.1484 880 (70.1%) 
History of mitral/aortic valve disease n (%) 75 (17.7%) 63 (14.9%) 65 (15.9%) 0.4573 203 (16.2%) 
History of renal impairment n (%) 161 (38.2%) 166 (39.6%) 138 (34.1%) 0.2312 465 (37.3%) 
History of liver disease n (%) 30 (7.1%) 36 (8.6%) 31 (7.7%) 0.7631 97 (7.8%) 
Previous PCI or CABG n (%) 136 (32.2%) 159 (37.6%) 150 (36.6%) 0.1779 445 (35.4%) 
On IV Nitrates at Randomization n (%) 73 (17.3%) 65 (15.3%) 69 (16.8%) 0.8622 207 (16.5%) 
IV Furosemide Dose through 24 hours (mg) Median (IQR) 40.0 (0.0, 120.0) 40.0 (0.0, 120.0) 40.0 (0.0, 120.0) 0.6385 40.0 (0.0, 120.0) 
Ace Inhibitors n (%) 224 (53.0%) 236 (55.7%) 204 (49.8%) 0.3622 664 (52.8%) 
Beta Blockers n (%) 201 (47.5%) 216 (50.9%) 176 (42.9%) 0.1905 593 (47.2%) 
Angiotensin Inhibitors n (%) 55 (13.0%) 41 (9.7%) 35 (8.5%) 0.0345 131 (10.4%) 
Calcium Channel Blockers n (%) 78 (18.4%) 42 (9.9%) 63 (15.4%) 0.1980 183 (14.6%) 
Oral Loop Diuretics n (%) 136 (32.2%) 121 (28.5%) 115 (28.0%) 0.1931 372 (29.6%) 
Systolic blood pressure (mmHg) Mean (SD) 147.3 (23.11) 126.8 (17.82) 121.9 (16.84) <.0001 132.1 (22.37) 
Respiratory rate (breaths/min) Mean (SD) 26.5 (4.43) 26.0 (3.87) 26.2 (4.22) 0.1661 26.2 (4.18) 
Heart rate (bpm) Mean (SD) 84.4 (16.97) 83.6 (18.16) 83.2 (17.78) 0.5998 83.7 (17.63) 
ECG QRS interval (ms) Mean (SD) 113.4 (35.40) 114.2 (36.22) 112.0 (34.82) 0.6713 113.2 (35.48) 
Baseline dyspnea VAS (mm) Mean (SD) 62.8 (23.57) 63.2 (23.12) 61.9 (23.06) 0.7096 62.6 (23.24) 
Albumin (g/L) Mean (SD) 38.0 (5.01) 37.4 (5.27) 37.8 (5.18) 0.3683 37.7 (5.16) 
ALT (U/L) Median (IQR) 18.2 (12.0, 29.0) 18.6 (12.7, 30.0) 18.7 (12.7, 28.1) 0.4938 18.6 (12.6, 29.1) 
BUN (mmol/L) Median (IQR) 8.2 (6.0, 11.2) 8.3 (6.4, 11.2) 7.9 (6.2, 11.0) 0.0204 8.2 (6.2, 11.1) 
Creatinine (umol/L) Mean (SD) 115.7 (40.08) 118.7 (36.82) 116.1 (39.16) 0.4711 116.8 (38.70) 
Hemoglobin (g/dL) Mean (SD) 13.4 (1.88) 13.3 (1.84) 13.4 (1.94) 0.9834 13.3 (1.88) 
 Statistic 
SysBP Chg (<= -19) 
(N=423) 
SysBP Chg (>-19 to <=-3) 
(N=424) 
SysBP Chg (> -3) 
(N=410) P-value [1] 
Overall 
(N=1257) 
Sodium (mmol/L) Mean (SD) 139.1 (3.92) 138.6 (4.06) 138.6 (4.03) 0.1231 138.7 (4.01) 
WBC (10**9/L) Mean (SD) 9.7 (3.58) 9.5 (3.70) 10.2 (4.18) 0.0162 9.8 (3.84) 
BNP (pg/mL) Median (IQR) 437.0 (153.0, 949.0) 419.0 (153.0, 968.0) 404.0 (152.0, 903.0) 0.6709 416.0 (153.0, 936.0) 
Troponin I (ng/mL) Median (IQR) 0.0400 (0.0005, 0.1260) 0.0350 (0.0005, 0.1290) 0.0340 (0.0005, 0.1285) 0.5221 0.0360 (0.0005, 0.1275) 
[1] P-value according to CMH chi-square for Categorical variables and F-test for Continuous variables  
Table 2: Univariable and Multivariable Associations of Baseline Characteristics with Systolic BP Decrease at 24 Hours 
  Univariable Models Multivariable Models 
Predictor 
Estimate for 
Change of: Estimate (95% CI) P-value Estimate (95% CI) P-value 
Age 10 0.23 (-0.67, 1.12) 0.623   
Gender: Males Yes vs. No -2.13 (-4.34, 0.09) 0.060   
Race: White Yes vs. No -3.13 (-6.31, 0.04) 0.053   
Time to randomization (hours) 1 -0.24 (-0.40, -0.08) 0.003   
BMI (kg/m2) 1 0.06 (-0.12, 0.24) 0.497   
Atrial fibrillation on admission Yes vs. No -4.40 (-6.87, -1.92) <0.001 -3.34 (-5.43, -1.26) 0.002 
History of CHF Yes vs. No -0.74 (-3.21, 1.74) 0.561   
History of COPD Yes vs. No -0.67 (-3.48, 2.14) 0.642   
History of diabetes Yes vs. No 0.80 (-1.38, 2.99) 0.470 -2.22 (-4.04, -0.40) 0.017 
History of hyperlipidemia Yes vs. No -0.49 (-2.77, 1.79) 0.675   
History of hypertension Yes vs. No 4.00 (1.28, 6.72) 0.004   
History of smoking Yes vs. No -1.60 (-5.70, 2.51) 0.446   
History of IHD, PVD, stroke Yes vs. No -0.73 (-3.11, 1.65) 0.550   
History of mitral/aortic valve disease Yes vs. No 0.75 (-2.21, 3.71) 0.618   
History of renal impairment Yes vs. No 0.39 (-1.87, 2.66) 0.732   
History of liver disease Yes vs. No 0.23 (-3.85, 4.31) 0.912   
Previous PCI or CABG Yes vs. No -1.98 (-4.26, 0.30) 0.089   
On IV Nitrates at Randomization Yes vs. No -0.12 (-3.06, 2.82) 0.936   
IV Furosemide Dose through 24 hours (mg) 5 -0.01 (-0.05, 0.04) 0.810   
Systolic blood pressure (mmHg) 1 0.47 (0.43, 0.51) <0.001 0.49 (0.45, 0.53) <0.001 
Respiratory rate <=24 breaths/min 5 -0.40 (-4.35, 3.56) 0.036   
Respiratory rate >24 breaths/min 5 2.03 (0.46, 3.59)    
Heart rate (bpm)* 94.50 vs. 82.00 0.35 (-0.42, 1.13) 0.357 1.33 (0.67, 1.99) <0.001 
 82.00 vs. 71.00 0.90 (-0.05, 1.85)  1.77 (0.98, 2.57)  
ECG QRS interval (ms) 1 0.00 (-0.03, 0.04) 0.777 0.05 (0.03, 0.08) <0.001 
Dyspnea VAS 1 0.02 (-0.03, 0.06) 0.478   
Albumin (g/L) 1 0.09 (-0.15, 0.32) 0.469   
ALT (U/I) Doubling -0.80 (-1.93, 0.34) 0.169   
BUN (mmol/L) Doubling 0.38 (-1.21, 1.96) 0.642 1.53 (0.18, 2.87) 0.026 
Creatinine <= 120 (umol/L) 5 -0.32 (-0.65, 0.01) 0.099   
Creatinine > 120 (umol/L) 5 0.22 (-0.02, 0.46)    
Hemoglobin (g/dL) 1 -0.00 (-0.58, 0.58) 0.992   
      * Non-linear association modeled as quadratic transformation. Estimates for the 75th percentile vs. the median, and for the median vs. the 25th 
percentile are presented. 
 
  
Sodium (mmol/L) 3 0.67 (-0.15, 1.49) 0.112   
WBC (10**9/L) 1 -0.27 (-0.56, 0.01) 0.060 -0.33 (-0.56, -0.09) 0.006 
BNP (pg/mL) Doubling 0.29 (-0.28, 0.86) 0.314   
Troponin-I (ng/mL) Doubling -0.03 (-0.30, 0.24) 0.848   
Treated with Tezosetan Yes vs. No 6.85 (4.71, 9.00) <.001 6.17 (4.39, 7.96) <0.001 
Figure 1: Association of SBP change at 24 hours with creatinine change at 72 hours.  The predicted value of the change in creatinine 
relative to the average change is plotted as a restricted cubic spline function of SBP change with knots at -45, -18, -4, 20 mmHg. 
Vertical tick marks represent individual patient values of the SBP change. Vertical reference lines for the 5th, 25th, 50th, 75th, and 95th 
percentiles of the SBP change distribution are shown. 
 
Figure 2: Association of SBP decrease by time from randomization with 180-day all-cause death.  The hazard ratio per 1-mmHg greater decrease 
in SBP with associated 95% confidence intervals is given. 
 
 
 
 
 
 
